Form 4 for MNKD MANNKIND CORP

Accepted 2022-05-12 00:00:00 ET · period of report 2022-05-10 · accession 0001209191-22-028680 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2022-05-12	2022-05-10	MNKD	Castagna Michael	CEO, Dir	A - Grant	$0.00	+565.0K	1.79M	+46%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Restricted Stock Unit	2022-05-10	A	A	311,000	$0.00	2,097,773	D	—	—	(F3) The restricted stock unit will vest on May 10, 2025 provided that the closing price of MannKind common stock on such vesting date is not less than the closing price on May 10, 2022. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from May 10, 2022 until May 10, 2025 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
2	Common	Restricted Stock Unit	2022-05-10	A	A	254,000	$0.00	1,786,773	D	—	—	(F2) Acquired pursuant to a Restricted Stock Unit Award: 25% vest on each year annivesary of the vesting determination date and 25% each anniversary thereafter; shares shall fully vest on the fourth year anniversary of the vesting determination date. (F1) Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.